
Spectrum Pharmaceuticals SPPI
Spectrum Pharmaceuticals Total Current Liabilities | SPPI
Annual Total Current Liabilities Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.7 M | 53.2 M | 53.1 M | 62 M | 98.3 M | 110 M | 65.5 M | 76.3 M | 109 M | 90 M | 123 M | 78.5 M | 63.3 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | 42.7 M | 78.9 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Actinium Pharmaceuticals
ATNM
|
7.97 M | $ 1.04 | -4.59 % | $ 32.4 M | ||
|
Oncternal Therapeutics
ONCT
|
5.2 M | - | -24.12 % | $ 1.56 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Concert Pharmaceuticals
CNCE
|
16.1 M | - | - | $ 401 M | ||
|
Histogen
HSTO
|
1.23 M | - | 31.6 % | $ 2.12 M | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
125 M | - | -7.23 % | $ 13 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
386 M | - | - | $ 1.62 B | ||
|
Omeros Corporation
OMER
|
78.1 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
PhaseBio Pharmaceuticals
PHAS
|
27.9 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
35.1 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
261 M | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
949 M | - | - | $ 26.6 B | ||
|
Provention Bio
PRVB
|
90.4 M | - | - | $ 2.37 B | ||
|
Reata Pharmaceuticals
RETA
|
59 M | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
2.44 M | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
40.4 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
2.07 M | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
15.3 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
37.7 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
149 M | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
57.9 M | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
7.55 M | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
7.39 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
17.3 M | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
37.2 M | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
53.9 M | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
46.4 M | - | -24.84 % | $ 2.64 M | ||
|
CohBar
CWBR
|
1.69 M | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
2.15 M | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
45.2 M | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
66.3 M | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
7.45 M | - | -48.37 % | $ 3.71 M | ||
|
Nabriva Therapeutics plc
NBRV
|
27.6 M | - | - | $ 4.55 M | ||
|
Annovis Bio
ANVS
|
3.64 M | $ 0.71 | -3.81 % | $ 14.6 M | ||
|
scPharmaceuticals
SCPH
|
14.9 M | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
9.71 M | - | - | $ 105 M | ||
|
Athersys
ATHX
|
38.4 M | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
88 M | - | - | $ 4.62 B | ||
|
Inozyme Pharma
INZY
|
33.9 M | - | - | $ 207 M | ||
|
NanoString Technologies
NSTG
|
58.9 M | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
56.2 M | - | -81.12 % | $ 4.28 M | ||
|
CNS Pharmaceuticals
CNSP
|
4.1 M | $ 3.56 | -9.07 % | $ 1.58 M | ||
|
Sorrento Therapeutics
SRNE
|
328 M | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
16.3 M | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
12.9 M | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
5.08 M | - | -61.37 % | $ 654 K |